Wei B Wu

US Patent:

20220259285, Aug 18, 2022

Filed:

Feb 22, 2022

Appl. No.:

17/677795

Inventors:

- Rockville MD, US
- Washington DC, US
Martin DEVENPORT - Gaithersburg MD, US
Wei WU - Washington DC, US
Xuexiang DU - Washington DC, US
Mingyue LIU - Washington DC, US
Fei TANG - Washington DC, US

Assignee:

ONCOC4, INC. - Rockville MD
CHILDREN'S NATIONAL MEDICAL CENTER - Washington DC

International Classification:

C07K 14/705
A61P 37/06
A61P 35/00
C07K 16/28
A61K 39/395
C07K 14/00

Abstract:

This invention relates to CTLA-4 protein compositions and their use in the mitigation of autoimmune adverse events associated with cancer immunotherapy.

US Patent:

20220259286, Aug 18, 2022

Filed:

Feb 22, 2022

Appl. No.:

17/677814

Inventors:

- Rockville MD, US
- Washington DC, US
Martin DEVENPORT - Gaithersburg MD, US
Wei WU - Washington DC, US
Xuexiang DU - Washington DC, US
Mingyue LIU - Washington DC, US
Fei TANG - Washington DC, US

Assignee:

ONCOC4, INC. - Rockville MD
CHILDREN'S NATIONAL MEDICAL CENTER - Washington DC

International Classification:

C07K 14/705
A61P 37/06
A61P 35/00
C07K 16/28
A61K 39/395
C07K 14/00

Abstract:

This invention relates to CTLA-4 protein compositions and their use in the mitigation of autoimmune adverse events associated with cancer immunotherapy.

US Patent:

20200399345, Dec 24, 2020

Filed:

Sep 1, 2020

Appl. No.:

17/009540

Inventors:

- Rockville MD, US
Wei Wu - Washington DC, US
Yang Liu - Baltimore MD, US
Pan Zheng - Baltimore MD, US

Assignee:

OncoImmune, Inc. - Rockville MD

International Classification:

C07K 14/705
C07K 14/435
C07K 19/00
C07K 14/47

Abstract:

Provided herein is a CD24 protein. The CD24 protein may include mature human or mouse CD24, as well as a N- or C-terminally fused portion of a mammalian immunoglobulin.

US Patent:

20190263889, Aug 29, 2019

Filed:

Sep 19, 2017

Appl. No.:

16/333888

Inventors:

- Rockville MD, US
- Washington DC, US
Martin DEVENPORT - Gaithersburg MD, US
Wei WU - Washington DC, US
Xuexiang DU - Washington DC, US
Mingyue LIU - Washington DC, US
Fei TANG - Washington DC, US

Assignee:

ONCOIMMUNE, INC. - Rockville MD
CHILDREN'S RESEARCH INSTITUTE, CHILDREN'S NATIONAL MEDICAL CENTER - Washington DC

International Classification:

C07K 14/705
C07K 16/28
A61P 35/00
A61P 37/06

Abstract:

This invention relates to cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) protein compositions and their use in the mitigation of autoimmune adverse events associated with cancer immunotherapy. Specifically, the disclosure provides a CTLA-4 protein comprising a mutant extracellular domain of CTLA-4, wherein the CTLA-4 protein exhibits reduced binding to an anti-CTLA-4 antibody as compared to a wild-type extracellular domain of CTLA-4, wherein the anti-CTLA-4 antibody has anti-cancer immunotherapeutic activity.

US Patent:

20190016783, Jan 17, 2019

Filed:

Aug 16, 2018

Appl. No.:

16/104072

Inventors:

- ROCKVILLE MD, US
Wei Wu - Washington DC, US
Yang Liu - Washington DC, US
Pan Zheng - Washington DC, US

Assignee:

ONCOLMMUNE, INC. - ROCKVILLE MD

International Classification:

C07K 14/705
C07K 14/47
C07K 14/435
C07K 19/00

Abstract:

Provided herein is a CD24 protein. The CD24 protein may include mature human or mouse CD24, as well as a N- or C-terminally fused portion of a mammalian immunoglobulin.

US Patent:

20170233453, Aug 17, 2017

Filed:

Feb 21, 2017

Appl. No.:

15/437968

Inventors:

- Rockville MD, US
Wei Wu - Washington DC, US
Yang Liu - Washington DC, US
Pan Zheng - Washington DC, US

International Classification:

C07K 14/705

Abstract:

Provided herein is a CD24 protein. The CD24 protein may include mature human or mouse CD24, as well as a N- or C-terminally fused portion of a mammalian immunoglobulin.